Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Landscape of Immunotherapy Resistance in NSCLC
Daniele Frisone, Alex Friedlaender, Alfredo Addeo, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Novel targets for immune-checkpoint inhibition in cancer
Maxime Borgeaud, José Luís Sandoval, Michel Obéid, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102614-102614
Open Access | Times Cited: 52
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, et al.
Annals of Oncology (2023) Vol. 35, Iss. 1, pp. 66-76
Closed Access | Times Cited: 34
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
Byoung Chul Cho, Jong Seok Lee, Yi‐Long Wu, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 12, pp. 1731-1742
Closed Access | Times Cited: 29
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Lee Jy, Richie R. Bhandare, Sai H. S. Boddu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116275-116275
Open Access | Times Cited: 8
A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery
Farangis Rastin, Mahsa Akbari Oryani, Sonia Iranpour, et al.
Journal of Materials Chemistry B (2023) Vol. 12, Iss. 4, pp. 872-894
Closed Access | Times Cited: 18
Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma
Shujie Huang, Jeff Yat‐Fai Chung, Chunjie Li, et al.
Cancer Letters (2024), pp. 217272-217272
Closed Access | Times Cited: 7
Forskolin affects proliferation, migration and Paclitaxel-mediated cytotoxicity in non-small-cell lung cancer cell lines via adenylyl cyclase/cAMP axis
Alessia Salzillo, Angela Ragone, Annamaria Spina, et al.
European Journal of Cell Biology (2023) Vol. 102, Iss. 2, pp. 151292-151292
Open Access | Times Cited: 14
Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
Ye‐Jin Kim, Wei Li, Doncho V. Zhelev, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 13
Centrosomal Protein 55 (CEP55) Drives Immune Exclusion and Resistance to Immune Checkpoint Inhibitors in Colorectal Cancer
Dechen Wangmo, Travis J Gates, Xianda Zhao, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 63-63
Open Access | Times Cited: 5
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
Annapaola Mariniello, Maxime Borgeaud, Marc Weiner, et al.
BioDrugs (2025)
Open Access
Function of antigen-presenting cells in non-small-cell lung cancer (NSCLC)
Rakesh Kumar, Kamal Jain, Shashi Raj K, et al.
Medical Oncology (2025) Vol. 42, Iss. 5
Closed Access
Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes
Danilo Rocco, Luigi Sapio, Luigi Della Gravara, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2433-2433
Open Access | Times Cited: 11
Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review
Hao Zhang, Yujun Hu, Tingting Wu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 4
Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application
Ru-Lan Wang, Zhenkun Liu, Ting Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Soluble PD-L1 and Serum Vascular Endothelial Growth Factor-B May Independently Predict Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab
Eleni Kokkotou, Dimitra Grapsa, Anna Papadopoulou, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 421-421
Open Access
PTEN-Mediated Resistance in Cancer: From Foundation to Future Therapies
Muhammad Tufail
Toxicology Reports (2025) Vol. 14, pp. 101987-101987
Open Access
Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach
Paweł Zieliński, Maria Stępień, Hanna Chowaniec, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 587-587
Open Access
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
Parth Malik, Ruma Rani, Raghu Solanki, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 850-895
Open Access | Times Cited: 10
Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices
Kátia Roque, Rossana Ruiz, Luís Más, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4547-4547
Open Access | Times Cited: 9
Disruption of NADPH homeostasis by total flavonoids from Adinandra nitida Merr. ex Li leaves triggers ROS-dependent p53 activation leading to apoptosis in non-small cell lung cancer cells
Taijin Lan, Songhua He, Xuefei Luo, et al.
Journal of Ethnopharmacology (2024) Vol. 332, pp. 118340-118340
Closed Access | Times Cited: 3
Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy
Yijiang Shi, Daniel Sanghoon Shin
Biomolecules (2023) Vol. 13, Iss. 6, pp. 984-984
Open Access | Times Cited: 7
The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients
Izabela Chmielewska, Anna Grenda, Paweł Krawczyk, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 4169-4177
Open Access | Times Cited: 7
MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?
Anna Grenda, Barbara Kuźnar-Kamińska, Ewa Kalinka‐Warzocha, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Strategies for engineering oncolytic viruses to enhance cancer immunotherapy
Ziyang Steve Yin, Zhengfeng Wang
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report
Douglas Dias e Silva, Guilherme Bes Borba, Juliana Rodrigues Beal, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 4209-4209
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top